博际生物官方网站

Bj-005 is a humanized anti programmed death ligand 1 (PD-L1) IgG1 monoclonal antibody and human transforming growth factor β （TGF- β） A recombinant bifunctional fusion protein fused from a part of the extracellular domain of receptor II, which can simultaneously target PD-L1 and TGF- β， It is used to treat cancer patients by targeting immune checkpoints and cytokine pathways that regulate tumor cell growth to inhibit tumor growth.

IL-15 is a multifunctional cytokine that plays a central role in the development, survival and activation of NK, t and B cells. IL-15 can not only increase the number of NK cells and T cells, but also activate NK cells and cytotoxic CD8 +t cells, thus killing tumors and other pathogens. Therefore, IL-15 has high therapeutic potential in the field of tumors and infectious diseases, ranking first among the 20 cancer immunotherapeutic drugs including PD-1 recommended by the National Cancer Institute (NCI) in 2008.

On July 6, the signing ceremony of BJ Bioscience Inc. (hereinafter referred to as "BJ Bioscience ") was successfully held in the Bluebay Life Science Park of Shanghai Lingang New Area. Dr. Joe Zhang, CEO of BJ Bioscience, Linkun Zou, Secretary of the Party Committee and Chairman of Lingang Fengxian Economic Development Company, signed the contract on behalf of both parties. Mars Qin, Chief Financial Officer, John Yu, Vice President and Head of Discovery biology, Daniel Jiang, Executive Director of CMC, Ziyan Zhu, Principal Scientist from BJ Bioscience and Xia Qu, Chief Industrial Planner, Aiying Ding, Assistant General Manager from Lingang Fengxian Ecomonic Development Company as well as other representatives from both parties attended the signing ceremony.

Bj-001 is the world's first tumor targeting IL-15 fusion protein independently developed by Boji biology and has a global patent. Its ingenious design not only overcomes the shortcoming of short half-life of recombinant IL-15, but also enables it to α v β 3, α v β 5 and α v β Integrin 6 is enriched in tumors with high expression, which has the potential to reduce systemic toxicity and enhance curative effect.

Company diagnostics (CDX) is an in vitro diagnosis (IVD) technology, which can provide information about the safety and effectiveness of patients' drugs for specific treatment, and help to determine the patient groups that can benefit from a certain treatment product, so as to improve the treatment effect, reduce toxic and side effects, and achieve precision medicine.

After employment, the company can apply for a one-time living allowance for talents in Hangzhou or Yuhang District (fresh graduates: 60000-80000 doctors, 50000-60000 masters, and 10000-40000 undergraduate students; first employment in Yuhang District within 7 years of non fresh graduates: 50000 doctors, 30000 masters, and 10000 undergraduate students)

Suqiao Biology (Suzhou) Co., Ltd. Boji biomedical technology today jointly announced that the two sides have reached cooperation on CMC research and clinical sample production of Boji biology's self-developed bifunctional antibody new drug (Product Code: bj-005), and reached a comprehensive strategic cooperation agreement on the future drug pipeline.